ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

April 28, 2020

The latest legislative package aimed at stabilizing the United States (U.S.) economy and bolstering the health care system during the COVID-19 crisis was recently signed into law. The ‘‘Paycheck Protection Program and Health Care Enhancement Act,’’ provides about $475 billion to key programs under the CARES Act, including the Paycheck Protection Program (PPP), and provides additional funds for COVID-19 testing and to aid hospitals and small businesses.

April 27, 2020

MedWatch Safety Alert was added to the FDA MedWatch webpage titled Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication.

April 24, 2020

On April 22, HHS announced the allocation of an additional $40.4 billion from the Public Health and Social Services Emergency Fund.

April 23, 2020

The American Society of Clinical Oncology (the Society) and its affiliate organization the Association for Clinical Oncology (the Association) announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on the coronavirus’ effect on individuals with cancer, and set forth a road to recovery as the cancer care delivery system prepares for life after COVID-19.

April 22, 2020

On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVYTM, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. 

April 22, 2020

The American Society of Clinical Oncology (ASCO) and the Association for Clinical Oncology (ASCO) released a news release announcing the COVID-19 and Cancer: Addressing a Healthcare System in Crisis presscast. 

April 20, 2020

The American Society of Clinical Oncology (ASCO) and the Association for Clinical Oncology (ASCO) released a news release announcing the COVID-19 and Cancer: Addressing a Healthcare System in Crisis presscast. 

April 20, 2020

On April 17, 2020, the Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE™, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

April 20, 2020

JCO Oncology Practice published an article and accompanying infographic  that examine the impact pharmacy benefit managers (PBMs) have on cancer care delivery. The article is part of the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series, which explores challenges and opportunities in today’s oncology delivery system.

April 17, 2020

On April 17, 2020, the Food and Drug Administration approved tucatinib (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

April 15, 2020

On April 15, 2020, the Food and Drug Administration approved mitomycin (JELMYTO, UroGen Pharma) for adult patients with low-grade upper tract urothelial cancer (LG-UTUC).

April 14, 2020

The American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS) hosted a weekly webinar series on caring for people with cancer during the COVID-19 pandemic and the webinars are now available online to view. 

April 10, 2020

The pre-publication review and dispute process for the Open Payments 2019 program year has begun. Physicians and teaching hospitals may review and dispute any updated records attributed to them until May 15. The Centers for Medicare & Medicaid Services (CMS) will publish its Open Payments program year 2019 data and any updates to previous program years’ data in June 2020.

How to Review Data

April 10, 2020

Alexandria, VA – The American Society of Clinical Oncology (ASCO) today launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. The registry will collect both baseline and follow up data throughout the COVID-19 pandemic and into 2021.

April 10, 2020

The Department of Health and Human Services (HHS) announced that COVID-19 relief payments to hospitals, physicians, and other health care providers will begin arriving via direct deposit on April 10, 2020—to eligible providers throughout the U.S. health care system. 

Pages